131 filings
Page 2 of 7
6-K
IMTX
Immatics N.V
10 Aug 23
Current report (foreign)
7:08am
6-K
IMTX
Immatics N.V
24 Jul 23
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
7:15am
6-K
IMTX
Immatics N.V
20 Jun 23
Current report (foreign)
4:20pm
6-K
IMTX
Immatics N.V
26 May 23
CONVENING NOTICE OF the ANNUAL GENERAL MEETING OF
6:04am
6-K
IMTX
Immatics N.V
16 May 23
Current report (foreign)
7:05am
6-K
IMTX
Immatics N.V
2 May 23
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
7:36am
6-K
IMTX
Immatics N.V
1 May 23
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
7:15am
20-F
2022 FY
IMTX
Immatics N.V
Annual report (foreign)
22 Mar 23
6:54am
6-K
IMTX
Immatics N.V
21 Mar 23
Current report (foreign)
6:03am
6-K
IMTX
Immatics N.V
13 Mar 23
Current report (foreign)
6:30am
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 23
Immatics / Nantahala Capital Management ownership change
5:02pm
SC 13G/A
IMTX
Immatics N.V
14 Feb 23
Immatics / BAKER BROS. ADVISORS ownership change
4:00pm
SC 13G/A
IMTX
Immatics N.V
10 Feb 23
Immatics / dievini Hopp BioTech holding GmbH & Co KG ownership change
4:01pm
SC 13G
IMTX
Immatics N.V
7 Feb 23
Immatics / WELLINGTON MANAGEMENT ownership change
12:00am
6-K
IMTX
Immatics N.V
9 Jan 23
Current report (foreign)
7:05am
6-K
IMTX
Immatics N.V
17 Nov 22
Current report (foreign)
7:13am
6-K
IMTX
Immatics N.V
10 Nov 22
Next-Generation TCR Bispecifics (TCER) Targeting Peptide-HLA Antigens for the Treatment of Patients with Solid Tumors
9:10am
6-K
IMTX
Immatics N.V
18 Oct 22
Current report (foreign)
8:05am
6-K
IMTX
Immatics N.V
12 Oct 22
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
10:55am
424B5
IMTX
Immatics N.V
11 Oct 22
Prospectus supplement for primary offering
6:30am